Abstract:Importance Clinical outcomes after acute coronary syndromes (ACS) or percutaneous coronary interventions (PCIs) in people living with HIV have not been characterized in sufficient detail, and extant data have not been synthesized adequately. Objective To better characterize clinical outcomes and postdischarge treatment of patients living with HIV after ACS or PCIs compared with patients in an HIV-negative control group. Data Sources Ovid MEDLINE, Embase, and Web of Science were searched for all available longitudinal studies of patients living with HIV after ACS or PCIs from inception until August 2023. Study Selection Included studies met the following criteria: patients living with HIV and HIV-negative comparator group included, patients presenting with ACS or undergoing PCI included, and longitudinal follow-up data collected after the initial event. Data Extraction and Synthesis Data extraction was performed following the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement. Clinical outcome data were pooled using a random-effects model meta-analysis. Main Outcome and Measures The following clinical outcomes were studied: all-cause mortality, major adverse cardiovascular events, cardiovascular death, recurrent ACS, stroke, new heart failure, total lesion revascularization, and total vessel revascularization. The maximally adjusted relative risk (RR) of clinical outcomes on follow-up comparing patients living with HIV with patients in control groups was taken as the main outcome measure. Results A total of 15 studies including 9499 patients living with HIV (pooled proportion [range], 76.4% [64.3%-100%] male; pooled mean [range] age, 56.2 [47.0-63.0] years) and 1 531 117 patients without HIV in a control group (pooled proportion [range], 61.7% [59.7%-100%] male; pooled mean [range] age, 67.7 [42.0-69.4] years) were included; both populations were predominantly male, but patients living with HIV were younger by approximately 11 years. Patients living with HIV were also significantly more likely to be current smokers (pooled proportion [range], 59.1% [24.0%-75.0%] smokers vs 42.8% [26.0%-64.1%] smokers) and engage in illicit drug use (pooled proportion [range], 31.2% [2.0%-33.7%] drug use vs 6.8% [0%-11.5%] drug use) and had higher triglyceride (pooled mean [range], 233 [167-268] vs 171 [148-220] mg/dL) and lower high-density lipoprotein-cholesterol (pooled mean [range], 40 [26-43] vs 46 [29-46] mg/dL) levels. Populations with and without HIV were followed up for a pooled mean (range) of 16.2 (3.0-60.8) months and 11.9 (3.0-60.8) months, respectively. On postdischarge follow-up, patients living with HIV had lower prevalence of statin (pooled proportion [range], 53.3% [45.8%-96.1%] vs 59.9% [58.4%-99.0%]) and β-blocker (pooled proportion [range], 54.0% [51.3%-90.0%] vs 60.6% [59.6%-93.6%]) prescriptions compared with those in the control group, but these differences were not statistically significant. There was a significantly increased risk among patients living with HIV vs those without HIV for all-cause mortality (RR, 1.64; 95% CI, 1.32-2.04), major adverse cardiovascular events (RR, 1.11; 95% CI, 1.01-1.22), recurrent ACS (RR, 1.83; 95% CI, 1.12-2.97), and admissions for new heart failure (RR, 3.39; 95% CI, 1.73-6.62). Conclusions and Relevance These findings suggest the need for attention toward secondary prevention strategies to address poor outcomes of cardiovascular disease among patients living with HIV.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is that among people infected with human immunodeficiency virus (HIV), the clinical outcomes after acute coronary syndrome (ACS) or percutaneous coronary intervention (PCI) have not been fully described, and the existing data have not been fully comprehensively analyzed. Specifically, the study aims to better describe and compare the clinical outcomes and treatment situations of HIV - infected patients and non - HIV - infected control group patients after discharge from ACS or PCI. ### Research Background With the wide use of highly active antiretroviral therapies (ARTs), the survival rate of HIV - infected people has significantly increased, resulting in an increase in the prevalence of age - related diseases, such as cardiovascular diseases (CVD), in this group. HIV - infected people have a higher risk of coronary artery disease, acute coronary syndrome (ACS) and heart failure, and the onset age is earlier. Therefore, understanding the long - term cardiovascular disease outcomes of these patients is crucial for formulating effective secondary prevention strategies. ### Research Objectives The main objective of the study is to compare the clinical outcomes and post - discharge treatment situations of HIV - infected and non - HIV - infected people through systematic review and meta - analysis, with particular attention to the following indicators: - All - cause mortality - Major adverse cardiovascular events (MACE) - Cardiovascular death - Recurrent ACS - Stroke - New - onset heart failure - Total lesion revascularization - Total vessel revascularization ### Research Methods The researchers retrieved all relevant longitudinal studies from the Ovid MEDLINE, Embase and Web of Science databases from the establishment of the databases to August 2023. The inclusion criteria include: including HIV - infected patients and non - HIV - infected control group patients, patients with ACS or receiving PCI treatment, and collecting longitudinal follow - up data after the initial event. ### Main Findings - HIV - infected people are about 11 years younger than the control group, but the risks of all - cause mortality, major adverse cardiovascular events, recurrent ACS and new - onset heart failure are significantly higher. - HIV - infected people are more likely to be current smokers and are more likely to use illegal drugs, and they have higher triglyceride levels and lower high - density lipoprotein cholesterol levels. - After discharge, the proportion of HIV - infected people using statins and beta - blockers is slightly lower, but the difference is not statistically significant. ### Conclusions The research results emphasize the need to focus on secondary prevention strategies for cardiovascular diseases in HIV - infected people in order to improve their survival rate and reduce the occurrence of adverse clinical outcomes. These findings are of great significance for formulating personalized medical plans for HIV - infected people.

Secondary Outcomes of Coronary Disease Among People With HIV

Clinical Characteristics and Outcomes Among People Living With HIV Undergoing Percutaneous Coronary Intervention: Insights From the Veterans Affairs Clinical Assessment, Reporting, and Tracking Program

Excess Risk for Atherosclerotic Cardiovascular Outcomes among US Adults with HIV in the Current Era

Higher cardiovascular disease risks in people living with HIV: A systematic review and meta-analysis

In-hospital outcomes of pulmonary hypertension in HIV patients: A population based cohort study

Atherosclerosis and HIV: Exploring Cardiovascular Risks and Management

Associations between post-acute sequelae of SARS-CoV-2, COVID-19 vaccination and HIV infection: a United States cohort study

The effect of HIV seropositivity on inpatient outcomes in atrial tachyarrhythmias: a US population analysis

Outcomes of Coronavirus Disease 2019 (COVID-19) Related Hospitalization Among People With Human Immunodeficiency Virus (HIV) in the ISARIC World Health Organization (WHO) Clinical Characterization Protocol (UK): A Prospective Observational Study

HIV-Associated Heart Failure: Phenotypes and Clinical Outcomes in a Safety-Net Setting

Clinical outcomes of ventricular assist device support by HIV infection status: An STS-INTERMACS analysis

Factors associated with the development of coronary artery disease in people with HIV

Association of Cardiologist Clinic Visits with Cardiovascular Primary Prevention Outcomes Among People with HIV from Underrepresented Racial and Ethnic Groups in the Southern United States

Prevention and treatment of cardiovascular disease in HIV: practical insights in an evolving field

Short Communication: Predictive Value of HIV-Related Versus Traditional Risk Factors for Coronary Atherosclerosis in People Aging with HIV

Assessment of Coronary Artery Disease With Computed Tomography Angiography and Inflammatory and Immune Activation Biomarkers Among Adults With HIV Eligible for Primary Cardiovascular Prevention

Primary prevention of cardiovascular disease in people living with HIV: a clinical update

Clinical outcomes and immunological response to SARS-CoV-2 infection among people living with HIV

Cardiovascular Disease Among Persons Living With HIV: New Insights Into Pathogenesis and Clinical Manifestations in a Global Context

Suboptimal HIV suppression is associated with progression of coronary artery stenosis: The multicenter AIDS cohort study (MACS) longitudinal coronary CT angiography study

HIV and cardiovascular risk: should we use other targets for cholesterol control? Brazilian data compared to major studies